stockrow
Saturday 7 November 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
- EPS
- −53.3%
- Free cash flow
- −66.6%
- Total debt
- −97.9%
Quarter to June 2026, against a year earlier
18.49
0.05
+0.27%
Follow GHRS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
28.70 | 23.04 | 34.13 | 28.32 |
+8 more quarters Free account |
Net Debt/EBITDA |
18.73 | 14.32 | 16.87 | 17.50 | |
Debt/Assets |
0.00% | 0.03% | 0.05% | 0.07% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.56 | 0.87 | 0.98 | |
Capex/Depreciation |
(0.19) | (0.69) | (0.22) | (0.44) | |
Interest Coverage |
(234.40) | (223.20) | (185.74) | (788.81) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.23) | (0.17) | (0.20) | (0.22) | |
Cash per Share |
5.45 | 4.31 | 4.60 | 4.65 | |
Shareholders Equity per Share |
5.40 | 4.25 | 4.58 | 4.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.40 | 4.25 | 4.58 | 4.70 | |
Free Cash Flow |
(15.04) | (10.73) | (12.35) | (13.72) | |
Working Capital |
355.97 | 260.42 | 277.60 | 284.38 | |
Capital Expenditures |
(0.02) | (0.06) | (0.02) | (0.04) | |
Net Current Asset Value |
355.97 | 260.34 | 277.45 | 284.17 | |
| Other line items | |||||
Quick Ratio |
28.22 | 22.63 | 33.50 | 27.72 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.23) | (0.17) | (0.20) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
4.69 | 4.99 | 3.76 | 3.39 | |
Average Assets |
342.89 | 297.86 | 238.25 | 250.82 | |
Average Common Equity |
331.33 | 286.80 | 229.33 | 240.38 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates